Phase II study of teniposide in patients with AIDS-related Kaposi's sarcoma. 1991

G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
AIDS and Oncology Unit, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil.

Antitumour activity of cytotoxic agents, evaluated in patients with AIDS-related Kaposi's sarcoma (KS), is about 30-80%. However, responses are mostly partial and short. Experience with etoposide is similar. Teniposide has a longer elimination half-life and superior antitumour activity compared with etoposide in some experimental models. Thus a phase II trial was done in 25 patients with AIDS-related KS. Teniposide was given by 60-min infusion at 360 mg/m2 every 3 weeks. 10 (40%) showed a partial response, median duration of 9 (6-20) weeks. The main side-effects were leukopenia, thrombocytopenia, nausea and vomiting, alopecia and mucositis.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000505 Alopecia Absence of hair from areas where it is normally present. Alopecia, Androgenetic,Baldness,Male Pattern Baldness,Pseudopelade,Alopecia Cicatrisata,Alopecia, Male Pattern,Androgenetic Alopecia,Androgenic Alopecia,Baldness, Male Pattern,Female Pattern Baldness,Hair Loss,Pattern Baldness,Alopecia Cicatrisatas,Alopecia, Androgenic,Alopecias, Androgenic,Androgenic Alopecias,Baldness, Female Pattern,Baldness, Pattern,Hair Losses,Loss, Hair,Losses, Hair,Male Pattern Alopecia
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's
D013713 Teniposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. Demethyl Epipodophyllotoxin Thenylidine Glucoside,NSC-122819,Teniposide, (5a alpha,9 alpha(S*))-Isomer,VM-26,Vumon,NSC 122819,NSC122819,VM 26,VM26

Related Publications

G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
January 1987, Cancer treatment reports,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
November 1989, Investigational new drugs,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
April 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
July 1992, International journal of dermatology,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
January 2009, Wiener klinische Wochenschrift,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
January 1988, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
March 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
January 2001, Indian journal of dermatology, venereology and leprology,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
November 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
G Schwartsmann, and E Sprinz, and M Kronfeld, and J Vinholes, and E Sander, and M Zampese, and R Preger, and L Kalakun, and A L Brunetto
May 2006, The Lancet. Oncology,
Copied contents to your clipboard!